Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Metastatic Melanoma With Relapsed Cutaneous Tumors Including Melanoma-in-transit

Next Previous
Trial Profile

An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Metastatic Melanoma With Relapsed Cutaneous Tumors Including Melanoma-in-transit

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etidaligide (Primary) ; Etidaligide (Primary) ; Chloroquine
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms DRIIM
  • Sponsors DNA Therapeutics

Most Recent Events

  • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
  • 03 May 2016 Results from Phase I part of this study published in the British Journal of Cancer
  • 04 Aug 2015 Results presented at the "Sarcoma and Cutaneous tumors" scientific session on 19th Oct 2015, as per DNA Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top